公开(公告)号：US20190000884A1

公开(公告)日：2019-01-03

申请号：US16064973

申请日：2016-12-22

申请人： Sangui Bio Pty. Ltd.

发明人： Elisabeth Karsten ,  Ben Herbert ,  Alan Liddle ,  Cameron Hill

IPC分类号： A61K35/18 ,  C12N5/078

摘要： The present disclosure relates to methods for modulating the level of proteins in a subject or in target cells by priming red blood cells with various agents or conditions that modulate the levels of proteins associated with red blood cells and administering the primed red blood cells to a subject. The disclosed methods represent a novel use of red blood cells primed to express a number of proteins, as cell therapies for numerous diseases or disorders.

公开(公告)号：US20180353546A1

公开(公告)日：2018-12-13

申请号：US16103453

申请日：2018-08-14

申请人： RegenLab USA LLC

发明人： Antoine Turzi ,  Donald Francois Du Toit

IPC分类号： A61K35/19 ,  A61L24/00 ,  A61L27/36 ,  A61L27/38 ,  A61Q19/08 ,  A61K8/98 ,  A61K35/28 ,  A61K35/30 ,  A61K35/32 ,  A61K35/34 ,  A61K35/35 ,  A61K35/38 ,  A61K35/39 ,  A61K38/48 ,  A61Q19/00 ,  A61K35/51 ,  A61L24/10 ,  A61L26/00 ,  A61M1/36 ,  A61K35/16 ,  A61K38/36 ,  A61K35/14 ,  A61K35/15 ,  A61K35/18 ,  A61K35/36

CPC分类号： A61K35/19 ,  A61K8/981 ,  A61K8/983 ,  A61K35/14 ,  A61K35/15 ,  A61K35/16 ,  A61K35/18 ,  A61K35/28 ,  A61K35/30 ,  A61K35/32 ,  A61K35/34 ,  A61K35/35 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/51 ,  A61K38/363 ,  A61K38/4833 ,  A61K2300/00 ,  A61K2800/87 ,  A61L24/0005 ,  A61L24/106 ,  A61L26/0042 ,  A61L26/0057 ,  A61L27/3691 ,  A61L27/3886 ,  A61L2430/02 ,  A61M1/3693 ,  A61M2202/0427 ,  A61Q19/00 ,  A61Q19/08 ,  C12Y304/21005

摘要： The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

公开(公告)号：US20180344770A1

公开(公告)日：2018-12-06

申请号：US15932341

申请日：2018-02-16

申请人： Rubius Therapeutics, Inc.

发明人： Tom Wickham ,  Tiffany F. Chen ,  Xuqing Zhang ,  Carolyn Hudak ,  Jordi Mata-Fink ,  Sivan Elloul ,  Billy Law ,  Lenka Hoffman ,  Kristian Eric Teichert ,  Shamael Rabia Dastagir

IPC分类号： A61K35/18

CPC分类号： C12N5/0641

摘要： Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods for use in human pharmaceutical and veterinary applications.

公开(公告)号：US10052349B2

公开(公告)日：2018-08-21

申请号：US15605696

申请日：2017-05-25

申请人： RegenLab USA LLC

发明人： Antoine Turzi ,  Donald Francois Du Toit

IPC分类号： A61L24/00 ,  A61L24/10 ,  A61L26/00 ,  A61M1/36 ,  A61K35/14 ,  A61K35/16 ,  A61K38/36 ,  A61K35/18 ,  A61K35/36 ,  A61Q19/00 ,  A61K8/98 ,  A61K35/19 ,  A61Q19/08 ,  A61K35/28 ,  A61K35/30 ,  A61K35/32 ,  A61K35/51 ,  A61K35/15 ,  A61L27/36 ,  A61L27/38 ,  A61K35/34 ,  A61K35/35 ,  A61K38/48 ,  A61K35/39 ,  A61K35/38

CPC分类号： A61K35/19 ,  A61K8/981 ,  A61K8/983 ,  A61K35/14 ,  A61K35/15 ,  A61K35/16 ,  A61K35/18 ,  A61K35/28 ,  A61K35/30 ,  A61K35/32 ,  A61K35/34 ,  A61K35/35 ,  A61K35/36 ,  A61K35/38 ,  A61K35/39 ,  A61K35/51 ,  A61K38/363 ,  A61K38/4833 ,  A61K2300/00 ,  A61K2800/87 ,  A61L24/0005 ,  A61L24/106 ,  A61L26/0042 ,  A61L26/0057 ,  A61L27/3691 ,  A61L27/3886 ,  A61L2430/02 ,  A61M1/3693 ,  A61M2202/0427 ,  A61Q19/00 ,  A61Q19/08 ,  C12Y304/21005

摘要： The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

公开(公告)号：US20180201889A1

公开(公告)日：2018-07-19

申请号：US15865901

申请日：2018-01-09

申请人： Massachusetts Institute of Technology

发明人： Armon R. Sharei ,  Klavs F. Jensen ,  James Robbins Abshire ,  Jacquin Clarence Niles

IPC分类号： C12M3/06 ,  C12M1/42 ,  C12N5/078 ,  A61K35/18

CPC分类号： C12M23/16 ,  A61K35/18 ,  C12M35/04 ,  C12N5/0641 ,  C12N5/0644 ,  C12N15/87 ,  C12N2521/00 ,  C12N2527/00

摘要： The current subject matter includes methods, systems, articles, and techniques to deliver material to anucleate cells, such as red blood cells. Using a rapid deformation based microfluidic system, loading of red blood cells with macromolecules of different sizes has been shown. Although delivery to some mammalian cells, such as cancer cell lines and fibroblasts had been previously demonstrated using this technique, those designs were incompatible with RBCs that have dramatically different physical properties. Through the use of smaller constriction sizes, high speeds and different buffers successful delivery to red blood cells can be achieved. By enabling robust delivery to red blood cells in a simple, scalable manner, the current subject matter can be implemented in a diversity of applications that deliver material to study red blood cell diseases and/or use red blood cells as a therapeutic platform. Related apparatus, systems, techniques, and articles are also described.

公开(公告)号：US20180161426A1

公开(公告)日：2018-06-14

申请号：US15574897

申请日：2016-05-19

申请人： Maria CAPPELLINI ,  CELGENE CORPORATION

发明人： Maria CAPPELLINI ,  Victoria SUNG

IPC分类号： A61K39/395 ,  A61P7/00 ,  A61K35/18 ,  A61K38/17 ,  G01N33/483 ,  C12Q1/02

摘要： Provided herein are methods of treating beta-thalassemia in a subject comprising administering to the subject an activin type II receptor (ActRII) signaling inhibitor (e.g., an activin ligand trap) and utilizing one or more in vitro cell culture methods provided herein in (i) selection of the subject to be treated according to the methods provided herein; and/or (ii) monitoring of the subject being treated according to the methods provided herein.

公开(公告)号：US09982230B2

公开(公告)日：2018-05-29

申请号：US15181195

申请日：2016-06-13

申请人： New York Blood Center, Inc.

发明人： Beth H. Shaz ,  Christopher D. Hillyer

IPC分类号： A61K35/14 ,  C12N5/078 ,  A61M1/02 ,  A01N1/02 ,  A61K35/16 ,  A61K35/18 ,  A61K35/19 ,  A61M1/34

CPC分类号： C12N5/0641 ,  A01N1/02 ,  A01N1/021 ,  A01N1/0226 ,  A61K35/14 ,  A61K35/16 ,  A61K35/18 ,  A61K35/19 ,  A61M1/0272 ,  A61M1/342 ,  A61M1/3496 ,  A61M2202/0429 ,  A61M2202/20 ,  C12N5/0644

摘要： The disclosure provides methods of making a cell-containing product having a uniform amount of cells therein. The method comprises pooling red blood cells from a plurality of blood units, and inactivating any pathogen contained therein. A storage solution added to the cellular component results in a cell-containing product that is essentially pathogen and white blood cell free and has an extended shelf life of about 42 to about 100 days. The cell-containing product is further divided into units which comprise a uniform dose of RBCs per unit.

公开(公告)号：US09901599B2

公开(公告)日：2018-02-27

申请号：US14748500

申请日：2015-06-24

申请人： Biomet Biologics, LLC

发明人： Alan Gray

IPC分类号： A61K35/18 ,  A61K31/19 ,  A61K31/70 ,  A01N1/02 ,  A01N1/00 ,  C12N5/078 ,  A61K35/12

CPC分类号： A61K35/18 ,  A01N1/00 ,  A01N1/0226 ,  A61K31/19 ,  A61K31/70 ,  A61K2035/124 ,  C12N5/0641 ,  C12N2501/999

摘要： Methods for treating blood. The methods comprise obtaining whole blood from a donor, mixing the whole blood with a red blood cell enhancement composition, and incubating the mixture of whole blood and red blood cell enhancement composition. The method can be performed at a time proximate to the time of obtaining blood from the donor, or after the blood has been stored for a period of time. The method rejuvenates red blood cells.

公开(公告)号：US09896660B2

公开(公告)日：2018-02-20

申请号：US14421191

申请日：2013-08-15

申请人： BOSTON MEDICAL CENTER CORPORATION ,  TRUSTEES OF BOSTON UNIVERSITY

发明人： George J. Murphy ,  David H. Sherr ,  Sarah S. Rozelle ,  Brenden W. Smith

IPC分类号： C12N5/0789 ,  C12N5/078 ,  A61K35/18 ,  A61K35/19 ,  G01N33/50 ,  G01N33/80 ,  G01N33/86

CPC分类号： C12N5/0647 ,  A61K31/404 ,  A61K31/655 ,  A61K35/18 ,  A61K35/19 ,  A61K45/06 ,  A61K2035/124 ,  C12N5/0641 ,  C12N5/0644 ,  C12N2501/60 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2506/03 ,  C12N2506/45 ,  G01N33/5044 ,  G01N33/80 ,  G01N33/86 ,  G01N2500/10

摘要： This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a MEP precursor cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) modulator. In some embodiments the AhR modulator is an AhR antagonist. In some embodiments the AhR modulator is an AhR agonist. In some embodiments the methods comprise culturing MEP precursor cells in the presence of an AHR antagonist and then culturing MEP precursor cells in the presence of an AHR agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR modulator are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs, among other things.

公开(公告)号：US20170355958A1

公开(公告)日：2017-12-14

申请号：US15529220

申请日：2015-11-24

申请人： CHILDREN'S MEDICAL CENTER CORPORATION

发明人： Vijay G. SANKARAN

IPC分类号： C12N5/078 ,  A61K35/18

CPC分类号： C12N5/0641 ,  A61K35/18 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/415 ,  C12N2501/998 ,  C12N2506/02 ,  C12N2506/03

摘要： Disclosed herein are methods for producing red blood cells (RBCs) from a population of stem cells and/or progenitor cells. In at least one of the stem cells or progenitor cells, SH2B3 protein activity is decreased, SH2B3 mRNA level is decreased, and/or SH2B3 protein level is decreased. The methods provided herein permit the production of RBCs with increased quantity and/or quality as compared to a method using the same population of stem cells and/or progenitor cells without SH2B3 inhibition or disruption. Also provided herein are methods of use of the RBCs produced using the methods described herein.